Corcept Therapeutics (CORT) Amortization of Deferred Charges (2012 - 2021)

Corcept Therapeutics has disclosed Amortization of Deferred Charges across 9 years of filings, most recently posting $508000.0 for Q4 2021.

• Amortization of Deferred Charges for Q4 2021 came in at $508000.0, up 4.96% year-over-year; the trailing twelve-month figure through Dec 2021 was $2.0 million (up 16.53% YoY), and the FY2021 annual result was $2.0 million, up 16.53% from the prior year.
• Amortization of Deferred Charges came in at $508000.0 for Q4 2021 at Corcept Therapeutics, up from $502000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $508000.0 in Q4 2021 to a low of $3000.0 in Q3 2017.
• The 4-year median for Amortization of Deferred Charges is $385000.0 (2020), against an average of $345933.3.
• Across the five-year window, Amortization of Deferred Charges tumbled 40.0% in 2017 and surged 45.78% in 2020, its largest moves.
• Corcept Therapeutics' Amortization of Deferred Charges stood at $3000.0 in 2017, then soared by 10966.67% to $332000.0 in 2019, then soared by 45.78% to $484000.0 in 2020, then rose by 4.96% to $508000.0 in 2021.
• The last three Amortization of Deferred Charges figures came in at $508000.0 (Q4 2021), $502000.0 (Q3 2021), and $496000.0 (Q2 2021), per Business Quant data.